

Risk-Based Stratification of MDS Based on the International Prognostic Scoring System (IPSS) and Proposed Modifications

						Risk Category	Numeric Score
Score	0	0.5	1.0	1.5	2.0	Low	0
Bone marrow myeloblasts	< 5%	5%-10%		11%-20%	21%-30% (considered AML)	Intermediate-1	0.5-1.0
						Intermediate-2	1.5-2.0
						High	≥ 2.5
Karyotype	Normal, or del(5q), del(Y), del(20q) as sole abnormalities	Other abnormalities	del(7), 7+, or 3+ abnormalities			<i>Proposed revision:</i> Favorable: del(12p), del(9q), t(15q), del(15q), 21 ⁺ , X ⁻ , t(7q), 21 ⁻ Intermediate-1: del(11q), 8 ⁺ Intermediate-2: t(11q23), any del(3q) abnormality, 19 ⁺ , del(7q), exactly 3 abnormalities Unfavorable: > 3 abnormalities and t(5q)	
Number of cytopenias	0, 1	2, 3	Anemia (hemoglobin < 10 g/dL), neutropenia (absolute neutrophil count < 1,800/μL), and/or thrombocytopenia (platelets < 100,000/μL)		<i>Proposed revision:</i> Adverse risk: Thrombocytopenia at presentation High transfusion burden		

The table is based on publications by Greenberg et al, 1997; Haase et al, 2007.

Reprinted with permission from Yarbro et al. *Cancer Nursing: Principles and Practice*. 7th ed. Jones and Bartlett Publishers, LLC; 2005. www.jbpub.com.